Best response after CAR T-cell infusion in the TL-pre-CAR-T set
| . | Evaluable patients in the TL-pre-CAR-T set . | |
|---|---|---|
| n = 11/15 . | ||
| Best response | ||
| CR | 4 | (36.4%) |
| PR | 1 | (9.1%) |
| Stable disease | 1 | (9.1%) |
| Progressive disease | 4 | (36.4%) |
| Not evaluated | 1 | (9.1%) |
| bORR∗ | ||
| bORR | 5 | (45.5%) |
| 95% confidence interval | (16.7%-76.6%) | |
| Time to best response (months) | ||
| N | 5 | |
| Missing | 0 | |
| Mean (SD) | 0.97 (0.055) | |
| Median | 0.99 | |
| Q1; Q3 | 1.0; 1.0 | |
| P1; P99 | 0.9; 1.0 | |
| . | Evaluable patients in the TL-pre-CAR-T set . | |
|---|---|---|
| n = 11/15 . | ||
| Best response | ||
| CR | 4 | (36.4%) |
| PR | 1 | (9.1%) |
| Stable disease | 1 | (9.1%) |
| Progressive disease | 4 | (36.4%) |
| Not evaluated | 1 | (9.1%) |
| bORR∗ | ||
| bORR | 5 | (45.5%) |
| 95% confidence interval | (16.7%-76.6%) | |
| Time to best response (months) | ||
| N | 5 | |
| Missing | 0 | |
| Mean (SD) | 0.97 (0.055) | |
| Median | 0.99 | |
| Q1; Q3 | 1.0; 1.0 | |
| P1; P99 | 0.9; 1.0 | |
SD, standard deviation.
Defined as (CR + PR).